Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance

Osman, 2001, Deep venous thrombosis and thalidomide therapy for multiple myeloma, N Engl J Med, 344, 1951, 10.1056/NEJM200106213442516 Baz, 2005, The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma, Mayo Clin Proc, 80, 1568, 10.4065/80.12.1568 Rajkumar, 2006, Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group, J Clin Oncol, 24, 431, 10.1200/JCO.2005.03.0221 Dimopoulos, 2007, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma, N Engl J Med, 357, 2123, 10.1056/NEJMoa070594 Facon, 2007, Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial, Lancet, 370, 1209, 10.1016/S0140-6736(07)61537-2 Palumbo, 2006, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial, Lancet, 367, 825, 10.1016/S0140-6736(06)68338-4 Hulin, 2009, Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial, J Clin Oncol, 27, 3664, 10.1200/JCO.2008.21.0948 Weber, 2003, Thalidomide alone or with dexamethasone for previously untreated multiple myeloma, J Clin Oncol, 21, 16, 10.1200/JCO.2003.03.139 Rajkumar, 2003, Thalidomide as initial therapy for early-stage myeloma, Leukemia, 17, 775, 10.1038/sj.leu.2402866 Cavo, 2004, First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma, Haematologica, 89, 826 Zonder, 2006, Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis, Blood, 108, 403, 10.1182/blood-2006-01-0154 Richardson, 2002, Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma, Blood, 100, 3063, 10.1182/blood-2002-03-0996 Morgan, 2007, Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients, Br J Haematol, 137, 268, 10.1111/j.1365-2141.2007.06538.x Gay, 2010, Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients, Blood, 115, 1343, 10.1182/blood-2009-08-239046 Harousseau, 2006, Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study, Haematologica, 91, 1498 Eby, 2009, Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias, Br J Haematol, 145, 151, 10.1111/j.1365-2141.2008.07577.x Palumbo, 2010, Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial, J Clin Oncol, 10.1200/JCO.2010.29.8216 Zangari, 2008, Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma, Haematologica, 93, 953, 10.3324/haematol.12522 Knight, 2006, Lenalidomide and venous thrombosis in multiple myeloma, N Engl J Med, 354, 2079, 10.1056/NEJMc053530 Rajkumar, 2010, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial, Lancet Oncol, 11, 29, 10.1016/S1470-2045(09)70284-0 Falanga, 2009, Venous thromboembolism in the hematologic malignancies, J Clin Oncol, 27, 4848, 10.1200/JCO.2009.22.8197 Kyle, 2004, Multiple myeloma, N Engl J Med, 351, 1860, 10.1056/NEJMra041875 Kristinsson, 2008, Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma, Blood, 112, 3582, 10.1182/blood-2008-04-151076 Kristinsson, 2010, Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study, Blood, 115, 4991, 10.1182/blood-2009-11-252072 Libourel, 2010, High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study, Blood, 10.1182/blood-2009-12-257519 Palumbo, 2008, Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma, Leukemia, 22, 414, 10.1038/sj.leu.2405062 2000, Prevention of pulmonary embolismdeep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial, Lancet, 355, 1295, 10.1016/S0140-6736(00)02110-3 Geerts, 2008, Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition), Chest, 133, 381S, 10.1378/chest.08-0656 Turpie, 1986, A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery, N Engl J Med, 315, 925, 10.1056/NEJM198610093151503 Ikhlaque, 2006, Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis, Am J Hematol, 81, 420, 10.1002/ajh.20625 Naess, 2007, Incidence and mortality of venous thrombosis: a population-based study, J Thromb Haemost, 5, 692, 10.1111/j.1538-7836.2007.02450.x Sorensen, 2000, Prognosis of cancers associated with venous thromboembolism, N Engl J Med, 343, 1846, 10.1056/NEJM200012213432504 Zangari, 2007, Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients, Blood Coagul Fibrinolysis, 18, 595, 10.1097/MBC.0b013e3281067fb2 Zangari, 2010, Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone, J Clin Oncol, 28, 132, 10.1200/JCO.2009.23.0169 Landgren, 2009, Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study, Blood, 113, 5412, 10.1182/blood-2008-12-194241 Muslimani, 2009, Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance, Clin Adv Hematol Oncol, 7, 827 Cohen, 2010, The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease, Thromb Res, 125, 216, 10.1016/j.thromres.2009.01.004 Sallah, 2004, The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance, Ann Oncol, 15, 1490, 10.1093/annonc/mdh385 Srkalovic, 2004, Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease, Cancer, 101, 558, 10.1002/cncr.20405 Gregersen, 2010, Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism, Eur J Haematol Berenson, 2010, Monoclonal gammopathy of undetermined significance: a consensus statement, Br J Haematol, 10.1111/j.1365-2141.2010.08207.x Heit, 2000, Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study, Arch Intern Med, 160, 809, 10.1001/archinte.160.6.809 Prandoni, 1992, Deep-vein thrombosis and the incidence of subsequent symptomatic cancer, N Engl J Med, 327, 1128, 10.1056/NEJM199210153271604 Landolfi, 2004, Efficacy and safety of low-dose aspirin in polycythemia vera, N Engl J Med, 350, 114, 10.1056/NEJMoa035572 van Marion, 2008, Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens, Leuk Res, 32, 1078, 10.1016/j.leukres.2007.12.002 Elice, 2006, Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism, Br J Haematol, 134, 399, 10.1111/j.1365-2141.2006.06208.x Zangari, 2007, Hemostatic dysfunction in paraproteinemias and amyloidosis, Semin Thromb Hemost, 33, 339, 10.1055/s-2007-976169 Green, 2009, Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism, Hematology Am Soc Hematol Educ Program, 259, 10.1182/asheducation-2009.1.259 Dunkley, 2007, Thalidomide causes platelet activation, which can be abrogated by aspirin, J Thromb Haemost, 5, 1323, 10.1111/j.1538-7836.2007.02542.x Fujita, 2001, Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2, Clin Cancer Res, 7, 3349 Johnson, 2008, Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping, Blood, 112, 4924, 10.1182/blood-2008-02-140434 Avcu, 2008, Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro, Thromb Res, 121, 567, 10.1016/j.thromres.2007.06.013 Sohn, 2005, Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B, Blood, 105, 3910, 10.1182/blood-2004-03-0928 Eroglu, 2008, Factor V 1691 G-A (Leiden) polymorphism and cancer-related venous thromboembolism: a meta-analysis of published studies, J BUON, 13, 61 Decousus, 2007, Thrombophilia and risk of venous thrombosis in patients with cancer, Thromb Res, 120, S51, 10.1016/S0049-3848(07)70130-5 Coppens, 2008, Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis, J Thromb Haemost, 6, 1474, 10.1111/j.1538-7836.2008.03055.x Barlogie, 2001, Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients, Blood, 98, 492, 10.1182/blood.V98.2.492 Prince, 2005, A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma, Clin Cancer Res, 11, 5504, 10.1158/1078-0432.CCR-05-0213 Rajkumar, 2002, Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma, J Clin Oncol, 20, 4319, 10.1200/JCO.2002.02.116 Palumbo, 2004, Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma, Hematol J, 5, 318, 10.1038/sj.thj.6200403 Offidani, 2004, Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma, Hematol J, 5, 312, 10.1038/sj.thj.6200401 Wu, 2006, Leuk Lymphoma, 47, 2335, 10.1080/10428190600821955 Zervas, 2004, Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study, Ann Oncol, 15, 134, 10.1093/annonc/mdh026 Barlogie, 2006, Thalidomide and hematopoietic-cell transplantation for multiple myeloma, N Engl J Med, 354, 1021, 10.1056/NEJMoa053583 Zangari, 2002, Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy, Blood, 100, 1168, 10.1182/blood-2002-01-0335 Wang, 2008, Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure, Blood, 112, 4445, 10.1182/blood-2008-02-141614 Weber, 2007, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America, N Engl J Med, 357, 2133, 10.1056/NEJMoa070596 Niesvizky, 2007, Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma, Leuk Lymphoma, 48, 2330, 10.1080/10428190701647887 Rajkumar, 2005, Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma, Blood, 106, 4050, 10.1182/blood-2005-07-2817 Baz, 2006, Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy, Ann Oncol, 17, 1766, 10.1093/annonc/mdl313 Minnema, 2004, Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy, Leukemia, 18, 2044, 10.1038/sj.leu.2403533 Klein, 2009, Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone, Ann Hematol, 88, 67, 10.1007/s00277-008-0561-1 Wang, 2005, Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma, Am J Hematol, 79, 194, 10.1002/ajh.20382 Zangari, 2004, Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation, Br J Haematol, 126, 715, 10.1111/j.1365-2141.2004.05078.x Offidani, 2006, Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma, Blood, 108, 2159, 10.1182/blood-2006-03-013086